GlassScriptPhysician profile
Imran A Patel
NPI 1922028125
$2,667.95
in general payments reported to CMS, 2019-2025
29 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $361 · 2021: $266 · 2022: $444 · 2023: $156 · 2024: $411 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Education: $62.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.72 |
| Education | $62.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.80 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $317.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.73 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $210.45 | 2019-2024 | Mounjaro |
| Abbott Laboratories | $208.11 | 2019-2025 | Freestyle Libre, Proclaim |
| Abbvie INC. | $206.44 | 2019-2025 | |
| Medtronic Minimed, INC. | $141.11 | 2019 | |
| Amgen INC. | $130.77 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $112.71 | 2019-2021 | |
| Dexcom, INC. | $91.04 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $68.62 | 2020-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $62.77 | 2020-2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $61.64 | 2020-2023 | Unithroid |
| Mannkind Corporation | $60.70 | 2025 | |
| Ibsa Pharma INC. | $57.34 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Companion Medical, INC. | $46.13 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.90 | 2019-2021 | |
| Horizon Therapeutics Plc | $36.46 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $34.44 | 2022-2024 | |
| Cequr Corporation | $26.61 | 2022-2024 | Cequr Simplicity |
| Sequel Med Tech, LLC | $18.44 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $18.23 | 2021 | |
| Pfizer INC. | $16.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.45 | 2020 | |
| Insulet Corporation | $13.64 | 2019 | |
| Shire North American Group INC | $13.35 | 2019 | |
| Tandem Diabetes Care, INC. | $12.78 | 2022 | |
| Clarus Therapeutics INC. | $12.70 | 2021 | |
| Medtronic, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.